{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T03:40:02Z","timestamp":1746416402410,"version":"3.40.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00277-025-06349-3","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T02:56:01Z","timestamp":1744253761000},"page":"2437-2448","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Follicular lymphoma grade 3A: aggressiveness and curability in an Asian cohort of 781 patients"],"prefix":"10.1007","volume":"104","author":[{"given":"Yaoyao","family":"Jing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghui","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haifeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongliang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yafei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"issue":"11","key":"6349_CR1","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","volume":"89","author":"A clinical evaluation of the International Lymphoma Study Group","year":"1997","unstructured":"A clinical evaluation of the International Lymphoma Study Group (1997) Classification of non-Hodgkin\u2019s lymphoma. The Non-Hodgkin\u2019s lymphoma classification project. Blood 89(11):3909\u20133918","journal-title":"Blood"},{"issue":"7","key":"6349_CR2","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3324\/haematol.12754","volume":"93","author":"PP Piccaluga","year":"2008","unstructured":"Piccaluga PP, Califano A, Klein U, Agostinelli C, Bellosillo B, Gimeno E et al (2008) Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas. Haematologica 93(7):1033\u20131038","journal-title":"Haematologica"},{"issue":"10","key":"6349_CR3","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.1182\/blood.V99.10.3806","volume":"99","author":"G Ott","year":"2002","unstructured":"Ott G, Katzenberger T, Lohr A, Kindelberger S, Rudiger T, Wilhelm M et al (2002) Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood 99(10):3806\u20133812","journal-title":"Blood"},{"issue":"9","key":"6349_CR4","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.3324\/haematol.2011.042531","volume":"96","author":"H Horn","year":"2011","unstructured":"Horn H, Schmelter C, Leich E, Salaverria I, Katzenberger T, Ott MM et al (2011) Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles. Haematologica 96(9):1327\u20131334","journal-title":"Haematologica"},{"issue":"20","key":"6349_CR5","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al (2016) The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood 127(20):2375\u20132390","journal-title":"Blood"},{"issue":"11","key":"6349_CR6","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM et al (2022) International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140(11):1200\u20131228","journal-title":"Blood"},{"issue":"2","key":"6349_CR7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1365-2141.2011.08942.x","volume":"156","author":"BE Wahlin","year":"2012","unstructured":"Wahlin BE, Yri OE, Kimby E, Holte H, Delabie J, Smeland EB et al (2012) Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times. Br J Haematol 156(2):225\u2013233","journal-title":"Br J Haematol"},{"issue":"5","key":"6349_CR8","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1093\/annonc\/mdq574","volume":"22","author":"J Shustik","year":"2011","unstructured":"Shustik J, Quinn M, Connors JM, Gascoyne RD, Skinnider B, Sehn LH (2011) Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy. Ann Oncol 22(5):1164\u20131169","journal-title":"Ann Oncol"},{"issue":"4","key":"6349_CR9","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.hoc.2020.02.002","volume":"34","author":"AA Patel","year":"2020","unstructured":"Patel AA, Smith SM (2020) Clinical and biological prognostic factors in follicular lymphoma. Hematol Oncol Clin North Am 34(4):647\u2013662","journal-title":"Hematol Oncol Clin North Am"},{"issue":"7","key":"6349_CR10","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1093\/annonc\/mdw185","volume":"27","author":"K Koch","year":"2016","unstructured":"Koch K, Hoster E, Ziepert M, Unterhalt M, Ott G, Rosenwald A et al (2016) Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL. Ann Oncol 27(7):1323\u20131329","journal-title":"Ann Oncol"},{"issue":"6","key":"6349_CR11","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1093\/annonc\/mdl039","volume":"17","author":"AK Ganti","year":"2006","unstructured":"Ganti AK, Weisenburger DD, Smith LM, Hans CP, Bociek RG, Bierman PJ et al (2006) Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska lymphoma study group experience. Ann Oncol 17(6):920\u2013927","journal-title":"Ann Oncol"},{"issue":"8","key":"6349_CR12","doi-asserted-by":"publisher","first-page":"863","DOI":"10.5858\/2004-128-863-ACEOFL","volume":"128","author":"ED Hsi","year":"2004","unstructured":"Hsi ED, Mirza I, Lozanski G, Hill J, Pohlman B, Karafa MT et al (2004) A clinicopathologic evaluation of follicular lymphoma grade 3A versus grade 3B reveals no survival differences. Arch Pathol Lab Med 128(8):863\u2013868","journal-title":"Arch Pathol Lab Med"},{"issue":"suppl 5","key":"6349_CR13","doi-asserted-by":"publisher","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","volume":"27","author":"M Dreyling","year":"2016","unstructured":"Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U, Ladetto M et al (2016) Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(suppl 5):v83\u2013v90","journal-title":"Ann Oncol"},{"key":"6349_CR14","unstructured":"Network NCC NCCN Guidelines Version 2.2023 Follicular Lymphoma (grade 1\u20132). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf. Accessed 09\/02\/2023"},{"issue":"5","key":"6349_CR15","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R et al (2004) Follicular lymphoma international prognostic index. Blood 104(5):1258\u20131265","journal-title":"Blood"},{"issue":"9","key":"6349_CR16","first-page":"2444","volume":"108","author":"A Barraclough","year":"2023","unstructured":"Barraclough A, England JT, Villa D, Wight J, Hapgood G, Conn J et al (2023) Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian lymphoma alliance. Haematologica 108(9):2444\u20132453","journal-title":"Haematologica"},{"issue":"12","key":"6349_CR17","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.clml.2017.07.002","volume":"17","author":"M Mustafa Ali","year":"2017","unstructured":"Mustafa Ali M, Rybicki L, Nomani L, Rouphail B, Dean RM, Hill BT et al (2017) Grade 3 follicular lymphoma: outcomes in the rituximab era. Clin Lymphoma Myeloma Leuk 17(12):797\u2013803","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"6349_CR18","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1200\/JCO.2012.42.4101","volume":"31","author":"OW Press","year":"2013","unstructured":"Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS et al (2013) Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol 31(3):314\u2013320","journal-title":"J Clin Oncol"},{"issue":"11","key":"6349_CR19","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1016\/j.humpath.2013.06.013","volume":"44","author":"AM Maeshima","year":"2013","unstructured":"Maeshima AM, Taniguchi H, Nomoto J, Miyamoto K, Fukuhara S, Munakata W et al (2013) Prognostic implications of histologic grade and intensity of Bcl-2 expression in follicular lymphomas undergoing rituximab-containing therapy. Hum Pathol 44(11):2529\u20132535","journal-title":"Hum Pathol"},{"issue":"3","key":"6349_CR20","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/ejh.13359","volume":"104","author":"S Mercadal","year":"2020","unstructured":"Mercadal S, Sancho JM, Climent F, Tapia G, Pomares H, Carro I et al (2020) Long-term outcome comparing histological grades of follicular lymphoma patients treated with immunochemotherapy as first-line therapy: A retrospective analysis from two institutions. Eur J Haematol 104(3):198\u2013206","journal-title":"Eur J Haematol"},{"issue":"4","key":"6349_CR21","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.3324\/haematol.2017.175059","volume":"103","author":"LM Rimsza","year":"2018","unstructured":"Rimsza LM, Li H, Braziel RM, Spier CM, Persky DO, Dunlap J et al (2018) Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort. Haematologica 103(4):e151\u2013e3","journal-title":"Haematologica"},{"issue":"1","key":"6349_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.beha.2017.11.002","volume":"31","author":"C Casulo","year":"2018","unstructured":"Casulo C (2018) Risk stratification in follicular lymphoma. Best Pract Res Clin Haematol 31(1):15\u201322","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"6349_CR23","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1182\/asheducation-2017.1.358","volume":"2017","author":"BS Kahl","year":"2017","unstructured":"Kahl BS (2017) Follicular lymphoma: are we ready for a risk-adapted approach? Hematol Am Soc Hematol Educ Program 2017(1):358\u2013364","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"6349_CR24","doi-asserted-by":"crossref","unstructured":"Barraclough A, England JT, Villa D, Wight J, Hapgood G, Conn J et al (2023) Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance. Haematologica","DOI":"10.3324\/haematol.2022.281375"},{"issue":"6","key":"6349_CR25","first-page":"1057","volume":"61","author":"T Anderson","year":"1977","unstructured":"Anderson T, Bender RA, Fisher RI, DeVita VT, Chabner BA, Berard CW et al (1977) Combination chemotherapy in non-Hodgkin\u2019s lymphoma: results of long-term followup. Cancer Treat Rep 61(6):1057\u20131066","journal-title":"Cancer Treat Rep"},{"issue":"7","key":"6349_CR26","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1200\/JCO.1994.12.7.1349","volume":"12","author":"NL Bartlett","year":"1994","unstructured":"Bartlett NL, Rizeq M, Dorfman RF, Halpern J, Horning SJ (1994) Follicular large-cell lymphoma: intermediate or low grade? J Clin Oncol 12(7):1349\u20131357","journal-title":"J Clin Oncol"},{"issue":"12","key":"6349_CR27","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1182\/blood.V85.12.3671.bloodjournal85123671","volume":"85","author":"AR Martin","year":"1995","unstructured":"Martin AR, Weisenburger DD, Chan WC, Ruby EI, Anderson JR, Vose JM et al (1995) Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood 85(12):3671\u20133678","journal-title":"Blood"},{"issue":"6","key":"6349_CR28","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1200\/JCO.1987.5.6.867","volume":"5","author":"P McLaughlin","year":"1987","unstructured":"McLaughlin P, Fuller LM, Velasquez WS, Butler JJ, Hagemeister FB, Sullivan-Halley JA et al (1987) Stage III follicular lymphoma: durable remissions with a combined chemotherapy-radiotherapy regimen. J Clin Oncol 5(6):867\u2013874","journal-title":"J Clin Oncol"},{"issue":"2","key":"6349_CR29","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3109\/10428194.2013.802778","volume":"55","author":"BE Wahlin","year":"2014","unstructured":"Wahlin BE, Sundstrom C, Sander B, Christensson B, Jeppsson-Ahlberg A, Hjalmarsson E et al (2014) Higher world health organization grades of follicular lymphoma correlate with better outcome in two nordic lymphoma group trials of rituximab without chemotherapy. Leuk Lymphoma 55(2):288\u2013295","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"6349_CR30","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1182\/blood.V79.4.1024.bloodjournal7941024","volume":"79","author":"F Cabanillas","year":"1992","unstructured":"Cabanillas F, Velasquez WS, Hagemeister FB, McLaughlin P, Redman JR (1992) Clinical, biologic, and histologic features of late relapses in diffuse large cell lymphoma. Blood 79(4):1024\u20131028","journal-title":"Blood"},{"issue":"3","key":"6349_CR31","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/ajh.25696","volume":"95","author":"A Freedman","year":"2020","unstructured":"Freedman A, Jacobsen E (2020) Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol 95(3):316\u2013327","journal-title":"Am J Hematol"},{"issue":"7","key":"6349_CR32","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3324\/haematol.2017.181024","volume":"103","author":"H Horn","year":"2018","unstructured":"Horn H, Kohler C, Witzig R, Kreuz M, Leich E, Klapper W et al (2018) Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2. Haematologica 103(7):1182\u20131190","journal-title":"Haematologica"},{"issue":"27","key":"6349_CR33","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U et al (2009) Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27(27):4555\u20134562","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06349-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06349-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06349-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T03:13:58Z","timestamp":1746414838000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06349-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["6349"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06349-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"11 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}